Developer docs
API playgroundTry for free, no card

Search company profiles

Acousia Therapeutics

Full company profile

uuid0002wwi

Namestring
Acousia Therapeutics
Legal namestring
Acousia Therapeutics GmbH
Websiteurl
acousia.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Acousia Therapeutics GmbH is a privately held, clinical-stage biotechnology company founded in 2012 and headquartered in Tübingen, Germany. The company develops small-molecule drug candidates that modulate the KCNQ4-encoded Kv7.4 potassium channel expressed in the outer hair cells of the cochlea, with a dual mode of action intended to both acutely enhance and chronically preserve natural hearing in patients with sensorineural hearing loss (SNHL). Its lead asset ACOU085 (international nonproprietary name: Bimokalner) is a first-in-class Kv7.4 activator formulated as a proprietary slow-release gel for transtympanic (local) administration, currently advancing through Phase 2 clinical development for the prevention of cisplatin-induced ototoxicity under the PROHEAR study conducted at 15 German university hospitals. A second pipeline candidate, ACOU082, is an orally bioavailable Kv7.4 activator in late preclinical development targeting chronic indications such as age-related hearing loss.

Acousia operates with a lean team of 1–10 employees and an exclusive research collaboration with the Translational Hearing Research Group of Tuebingen University Clinic under Prof. Dr. Hubert Löwenheim. The company is pre-revenue and funds operations through equity capital from a syndicate led by the Boehringer Ingelheim Venture Fund and including Axxam, Bregua, Creathor, KfW, LBBW Venture, and (since January 2024) Esperante Ventures; total disclosed equity raised is approximately $14.6 million across rounds in 2016 and 2018, with the 2024 round amount undisclosed. Its intellectual property position comprises two granted composition-of-matter patents and one pending formulation patent covering the sustained-release gel.

The company's go-to-market model is enterprise-style partnering rather than direct commercialization: it conducts clinical trials at major German university hospitals, engages key opinion leaders in otolaryngology, and targets late-stage development and commercialization partnerships with larger pharmaceutical companies. Pricing is not disclosed because no product is approved; revenue mechanics are expected to derive from either future direct sales or, more likely, licensing/out-licensing economics following Phase 3 and regulatory approval. Target end-user segments include cancer patients receiving ototoxic chemotherapy, patients with age-related hearing loss, noise-induced hearing loss, sudden sensorineural hearing loss, and hearing-aid or cochlear-implant users seeking adjunctive therapy.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersTübingen, Germany
HQ citystring
Tübingen
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
otoprotective therapeutics, hearing loss drugs, small molecule pharmaceuticals, otology biotech, Kv7.4 channel activators
Industry2 codes
PRIMARYHLAKAMAC
Otology & Neurotology (Ear/Hearing/Balance)
SECONDARYHLAKAMAI
Audiology & Hearing Services (ENT-Affiliated)
Product category
Otolaryngology Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Revenue
TypeOne Time License
Description

Pre-revenue clinical-stage biotech company. Revenue model expected to derive from sales of proprietary small molecule drug candidates upon regulatory approval. Target market includes acute hearing loss prevention (cisplatin-induced ototoxicity) and chronic hearing loss treatment (age-related hearing loss, noise-induced hearing loss).

acousia.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Acousia Therapeutics develops small molecule drug candidates that activate the Kv7.4 potassium channel in outer hair cells of the cochlea to enhance and preserve natural hearing in patients with sensorineural hearing loss. Its lead program ACOU085 (Bimokalner) is a locally administered otoprotectant in Phase 2 trials for cisplatin-induced hearing loss, and ACOU082 is an oral Kv7.4 activator in late preclinical development for chronic indications such as age-related hearing loss.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • More than 90% of participants developed ototoxicity after three cisplatin cycles; ACOU085-treated patients showed clinically meaningful prevention of pure-tone audiometry threshold increases compared to placebo
+2 more records
Product overview1 text field

Acousia Therapeutics develops a pipeline of small molecule drug candidates for the prevention and treatment of sensorineural hearing loss (SNHL). The core products are ACOU085 (Bimokalner), a locally-administered otoprotective agent in Phase 2 clinical development for acute hearing loss conditions like cisplatin-induced ototoxicity, and ACOU082, an orally-administered Kv7.4 activator in late preclinical development for chronic hearing loss conditions such as age-related hearing loss. Both candidates employ a unique dual mode of action targeting outer hair cells in the cochlea to enhance and preserve natural hearing.

Product and service2 records
1ACOU085 (INN: Bimokalner)
CategoryOtolaryngology Pharmaceuticals / Otoprotectants
Description

First-in-class etiology-agnostic otoprotective small molecule that modulates the KCNQ4-encoded Kv7.4 potassium channel in cochlear outer hair cells, delivered locally via transtympanic injection using a proprietary sustained-release gel formulation. Currently in Phase 2 development for cisplatin-induced hearing loss (PROHEAR study) with planned indications including aminoglycoside ototoxicity, CI surgery hearing preservation, and sudden sensorineural hearing loss.

2ACOU082
CategoryOtolaryngology Pharmaceuticals / Chronic Hearing Loss Therapeutics
Description

Proprietary, orally administered small-molecule Kv7.4 activator designed for chronic progressive disorders such as age-related hearing loss, with potential to acutely enhance natural hearing and preserve hearing capacity. Currently in late preclinical stage targeting age-related hearing loss, broader chronic hearing loss, hearing aid synergistic enhancement, and chronic noise overexposure.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1UKT Translational Hearing Research Group of Tuebingen University
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Exclusive collaboration agreement with the renowned Translational Hearing Research Group of Tuebingen University Clinic. This partnership provides exclusive access to best-in-class hearing research capabilities for preclinical and clinical development of Acousia's drug candidates. Prof. Dr. Hubert Löwenheim serves as Chair and Medical Director of OHNS University Clinic Tuebingen and Principal Investigator of the research group.

acousia.com
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Partnership with the Hearing Loss Association of America, a leading patient advocacy organization providing support and resources for people with hearing loss.

3Royal National Institute for Deaf People (RNID, UK)
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Collaboration with RNID, a UK-based charity providing support for people with hearing loss. Acousia presented at the 2023 Hearing Therapeutics Summit organized in partnership with RNID, University College London Ear Institute, and National Institute for Health and Care Research.

acousia.com
4Stiftung Tinnitus und Hören Charité (Germany)
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Partnership with Stiftung Tinnitus und Hören Charité, a German foundation focused on tinnitus and hearing research based at Charité university hospital in Berlin.

acousia.com
5German Society of Otorhinolaryngology (DSZ-HNO)
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

The PROHEAR Study was formally endorsed by the Study Group of the German Society of Otorhinolaryngology (DSZ-HNO). The study is conducted at major university clinics across Germany under regulatory supervision.

acousia.com
6German Society of Urology (DGU)
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

The German Society of Urology highlighted Acousia's PROHEAR Study as 'Study of the Month,' acknowledging the urgent need for effective prevention of cisplatin-induced hearing loss in testicular cancer treatment.

acousia.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

French clinical-stage biotech developing small-molecule therapies for hearing loss disorders including sudden SNHL and other inner ear conditions. Closely comparable to Acousia in therapeutic focus (SNHL pharma) and stage (Phase 2).

TypeDirect peer
Description

Clinical-stage biotech developing gene therapies for hearing and balance disorders, acquired by Eli Lilly in 2023. Directly comparable to Acousia in pursuing therapeutics that target the inner ear for hearing loss.

3Otonomy
TypeDirect peer
Description

Clinical-stage biotech specializing in otic (ear) therapeutics for hearing loss and balance disorders, with a portfolio of locally-delivered ear drugs. Comparable to Acousia in therapeutic area and specialty ear drug delivery focus.

TypeDirect peer
Description

Previously a clinical-stage biotech developing small-molecule regenerative therapies (FX-322) for sensorineural hearing loss. Highly comparable to Acousia as a prior direct competitor in SNHL small-molecule drug development.

5Sound Pharmaceuticals
TypeDirect peer
Description

Clinical-stage biotech developing oral small-molecule therapeutics such as SPI-1005 for noise-induced and ototoxicity-related hearing loss. Comparable to Acousia in small-molecule modality and overlapping SNHL indications.

TypeDirect peer
Description

Clinical-stage German biotech developing small-molecule therapeutics for acute and chronic inner ear disorders. Directly comparable to Acousia in geography, therapeutic focus, and small-molecule drug development approach.

TypeDirect peer
Description

UK clinical-stage biotech developing cell-based therapies for hearing loss, including auditory neuropathy. Comparable to Acousia as a Europe-based emerging player in SNHL therapeutics with a differentiated modality.

TypeBroad incumbent
Description

Major global pharmaceutical company that acquired Decibel Therapeutics in 2023, signaling strategic commitment to hearing therapeutics. Broad incumbent with the resources to develop and commercialize SNHL treatments globally.

9Boehringer Ingelheim
TypeBroad incumbent
Description

Major global pharmaceutical company whose venture arm (BIVF) is the lead investor in Acousia Therapeutics. Broad incumbent with a direct strategic interest in Acousia's success and potential to be a future acquirer of the company.

TypeBroad incumbent
Description

Major global pharmaceutical company with historical programs and partnerships in hearing therapeutics. Broad incumbent that could compete with or partner with Acousia in the SNHL therapeutics space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Acousia Therapeutics

Otolaryngology Pharmaceuticalsacousia.com

What Acousia Therapeutics does

Acousia Therapeutics GmbH is a privately held, clinical-stage biotechnology company founded in 2012 and headquartered in Tübingen, Germany. The company develops small-molecule drug candidates that modulate the KCNQ4-encoded Kv7.4 potassium channel expressed in the outer hair cells of the cochlea, with a dual mode of action intended to both acutely enhance and chronically preserve natural hearing in patients with sensorineural hearing loss (SNHL). Its lead asset ACOU085 (international nonproprietary name: Bimokalner) is a first-in-class Kv7.4 activator formulated as a proprietary slow-release gel for transtympanic (local) administration, currently advancing through Phase 2 clinical development for the prevention of cisplatin-induced ototoxicity under the PROHEAR study conducted at 15 German university hospitals. A second pipeline candidate, ACOU082, is an orally bioavailable Kv7.4 activator in late preclinical development targeting chronic indications such as age-related hearing loss.

Acousia operates with a lean team of 1–10 employees and an exclusive research collaboration with the Translational Hearing Research Group of Tuebingen University Clinic under Prof. Dr. Hubert Löwenheim. The company is pre-revenue and funds operations through equity capital from a syndicate led by the Boehringer Ingelheim Venture Fund and including Axxam, Bregua, Creathor, KfW, LBBW Venture, and (since January 2024) Esperante Ventures; total disclosed equity raised is approximately $14.6 million across rounds in 2016 and 2018, with the 2024 round amount undisclosed. Its intellectual property position comprises two granted composition-of-matter patents and one pending formulation patent covering the sustained-release gel.

The company's go-to-market model is enterprise-style partnering rather than direct commercialization: it conducts clinical trials at major German university hospitals, engages key opinion leaders in otolaryngology, and targets late-stage development and commercialization partnerships with larger pharmaceutical companies. Pricing is not disclosed because no product is approved; revenue mechanics are expected to derive from either future direct sales or, more likely, licensing/out-licensing economics following Phase 3 and regulatory approval. Target end-user segments include cancer patients receiving ototoxic chemotherapy, patients with age-related hearing loss, noise-induced hearing loss, sudden sensorineural hearing loss, and hearing-aid or cochlear-implant users seeking adjunctive therapy.

Acousia Therapeutics firmographics

Firmographics
Name
Acousia Therapeutics
Legal name
Acousia Therapeutics GmbH
Website
https://acousia.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Acousia Therapeutics industry classification

Industry
Product category
Otolaryngology Pharmaceuticals
akta.pro industry
PRIMARYHLAKAMAC
Otology & Neurotology (Ear/Hearing/Balance)
SECONDARYHLAKAMAI
Audiology & Hearing Services (ENT-Affiliated)

Keywords

  • Otoprotective therapeutics
  • Hearing loss drugs
  • Small molecule pharmaceuticals
  • Otology biotech
  • Kv7.4 channel activators

Where Acousia Therapeutics is headquartered

Location

Headquarters

HQ city
Tübingen
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Acousia Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Revenue: Pre-revenue clinical-stage biotech company. Revenue model expected to derive from sales of proprietary small molecule drug candidates upon regulatory approval. Target market includes acute hearing loss prevention (cisplatin-induced ototoxicity) and chronic hearing loss treatment (age-related hearing loss, noise-induced hearing loss).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Acousia Therapeutics product offering

Product offering

Core offering

Acousia Therapeutics develops small molecule drug candidates that activate the Kv7.4 potassium channel in outer hair cells of the cochlea to enhance and preserve natural hearing in patients with sensorineural hearing loss. Its lead program ACOU085 (Bimokalner) is a locally administered otoprotectant in Phase 2 trials for cisplatin-induced hearing loss, and ACOU082 is an oral Kv7.4 activator in late preclinical development for chronic indications such as age-related hearing loss.

Product overview

Acousia Therapeutics develops a pipeline of small molecule drug candidates for the prevention and treatment of sensorineural hearing loss (SNHL). The core products are ACOU085 (Bimokalner), a locally-administered otoprotective agent in Phase 2 clinical development for acute hearing loss conditions like cisplatin-induced ototoxicity, and ACOU082, an orally-administered Kv7.4 activator in late preclinical development for chronic hearing loss conditions such as age-related hearing loss. Both candidates employ a unique dual mode of action targeting outer hair cells in the cochlea to enhance and preserve natural hearing.

Differentiator

Problem solved

Functional benefit

Products and services

  • ACOU085 (INN: Bimokalner) First-in-class etiology-agnostic otoprotective small molecule that modulates the KCNQ4-encoded Kv7.4 potassium channel in cochlear outer hair cells, delivered locally via transtympanic injection using a proprietary sustained-release gel formulation. Currently in Phase 2 development for cisplatin-induced hearing loss (PROHEAR study) with planned indications including aminoglycoside ototoxicity, CI surgery hearing preservation, and sudden sensorineural hearing loss.
  • ACOU082 Proprietary, orally administered small-molecule Kv7.4 activator designed for chronic progressive disorders such as age-related hearing loss, with potential to acutely enhance natural hearing and preserve hearing capacity. Currently in late preclinical stage targeting age-related hearing loss, broader chronic hearing loss, hearing aid synergistic enhancement, and chronic noise overexposure.

Quantifiable outcome

  • More than 90% of participants developed ototoxicity after three cisplatin cycles; ACOU085-treated patients showed clinically meaningful prevention of pure-tone audiometry threshold increases compared to placebo
  • +2 more outcomes

Companies that use Acousia Therapeutics

Customer profile

Named customers1 record

Segments5 records

Ideal customer profiles3 records

Acousia Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Acousia Therapeutics partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and supporting.

  • UKT Translational Hearing Research Group of Tuebingen UniversitycoreStrategic or Co-development PartnerExclusive collaboration agreement with the renowned Translational Hearing Research Group of Tuebingen University Clinic. This partnership provides exclusive access to best-in-class hearing research capabilities for preclinical and clinical development of Acousia's drug candidates. Prof. Dr. Hubert Löwenheim serves as Chair and Medical Director of OHNS University Clinic Tuebingen and Principal Investigator of the research group.
  • Hearing Loss Association of America (HLAA)supportingStrategic or Co-development PartnerPartnership with the Hearing Loss Association of America, a leading patient advocacy organization providing support and resources for people with hearing loss.
  • Royal National Institute for Deaf People (RNID, UK)supportingStrategic or Co-development PartnerCollaboration with RNID, a UK-based charity providing support for people with hearing loss. Acousia presented at the 2023 Hearing Therapeutics Summit organized in partnership with RNID, University College London Ear Institute, and National Institute for Health and Care Research.
  • Stiftung Tinnitus und Hören Charité (Germany)supportingStrategic or Co-development PartnerPartnership with Stiftung Tinnitus und Hören Charité, a German foundation focused on tinnitus and hearing research based at Charité university hospital in Berlin.
  • German Society of Otorhinolaryngology (DSZ-HNO)supportingStrategic or Co-development PartnerThe PROHEAR Study was formally endorsed by the Study Group of the German Society of Otorhinolaryngology (DSZ-HNO). The study is conducted at major university clinics across Germany under regulatory supervision.
  • German Society of Urology (DGU)supportingStrategic or Co-development PartnerThe German Society of Urology highlighted Acousia's PROHEAR Study as 'Study of the Month,' acknowledging the urgent need for effective prevention of cisplatin-induced hearing loss in testicular cancer treatment.

Scale indicators7 records

Recent moves5 records

Expansion highlights5 records

Acousia Therapeutics competitors and assessment

Company assessment

Direct peers

  • Sensorion: French clinical-stage biotech developing small-molecule therapies for hearing loss disorders including sudden SNHL and other inner ear conditions. Closely comparable to Acousia in therapeutic focus (SNHL pharma) and stage (Phase 2).
  • Decibel Therapeutics: Clinical-stage biotech developing gene therapies for hearing and balance disorders, acquired by Eli Lilly in 2023. Directly comparable to Acousia in pursuing therapeutics that target the inner ear for hearing loss.
  • Otonomy: Clinical-stage biotech specializing in otic (ear) therapeutics for hearing loss and balance disorders, with a portfolio of locally-delivered ear drugs. Comparable to Acousia in therapeutic area and specialty ear drug delivery focus.
  • Frequency Therapeutics: Previously a clinical-stage biotech developing small-molecule regenerative therapies (FX-322) for sensorineural hearing loss. Highly comparable to Acousia as a prior direct competitor in SNHL small-molecule drug development.
  • Sound Pharmaceuticals: Clinical-stage biotech developing oral small-molecule therapeutics such as SPI-1005 for noise-induced and ototoxicity-related hearing loss. Comparable to Acousia in small-molecule modality and overlapping SNHL indications.
  • AudioCure Pharma: Clinical-stage German biotech developing small-molecule therapeutics for acute and chronic inner ear disorders. Directly comparable to Acousia in geography, therapeutic focus, and small-molecule drug development approach.
  • Rinri Therapeutics: UK clinical-stage biotech developing cell-based therapies for hearing loss, including auditory neuropathy. Comparable to Acousia as a Europe-based emerging player in SNHL therapeutics with a differentiated modality.

Broad incumbents

  • Eli Lilly: Major global pharmaceutical company that acquired Decibel Therapeutics in 2023, signaling strategic commitment to hearing therapeutics. Broad incumbent with the resources to develop and commercialize SNHL treatments globally.
  • Boehringer Ingelheim: Major global pharmaceutical company whose venture arm (BIVF) is the lead investor in Acousia Therapeutics. Broad incumbent with a direct strategic interest in Acousia's success and potential to be a future acquirer of the company.
  • Novartis: Major global pharmaceutical company with historical programs and partnerships in hearing therapeutics. Broad incumbent that could compete with or partner with Acousia in the SNHL therapeutics space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Acousia Therapeutics social profiles

Digital presence

Acousia Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Acousia Therapeutics leadership team

Management profile

Number of profiles

Profiles7 records

Acousia Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Acousia Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acousia Therapeutics

What does Acousia Therapeutics do?

Acousia Therapeutics develops small molecule drug candidates that activate the Kv7.4 potassium channel in outer hair cells of the cochlea to enhance and preserve natural hearing in patients with sensorineural hearing loss. Its lead program ACOU085 (Bimokalner) is a locally administered otoprotectant in Phase 2 trials for cisplatin-induced hearing loss, and ACOU082 is an oral Kv7.4 activator in late preclinical development for chronic indications such as age-related hearing loss.

Is Acousia Therapeutics a public or private company?

Acousia Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Acousia Therapeutics founded?

Acousia Therapeutics was founded in 2012. It employs 1 to 10 people.

Where is Acousia Therapeutics based?

Acousia Therapeutics is headquartered in Tübingen, Germany, in the Europe region.

How does Acousia Therapeutics make money?

One revenue line is on record: pharmaceutical Product Revenue.

Who are Acousia Therapeutics's main competitors?

Direct peers on record are Sensorion, Decibel Therapeutics, Otonomy, Frequency Therapeutics, Sound Pharmaceuticals, AudioCure Pharma and Rinri Therapeutics. Broad incumbents are Eli Lilly, Boehringer Ingelheim and Novartis.

Does Acousia Therapeutics have an API?

No public API is recorded for Acousia Therapeutics.

What industry is Acousia Therapeutics in?

Acousia Therapeutics's product category is Otolaryngology Pharmaceuticals. Its primary akta.pro industry code is HLAKAMAC, Otology & Neurotology (Ear/Hearing/Balance), with a secondary code of HLAKAMAI, Audiology & Hearing Services (ENT-Affiliated).

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswirePromising First-in-Patient Results for ACOU085 (INN: Bimokalner) in Cisplatin-Induced OtotoxicityAcousia Therapeutics GmbH announced positive top-line efficacy results from its completed Phase 2a PROHEAR Study evaluating ACOU085 (Bimokalner) for preventing cisplatin-induced sensorineural hearing loss in testicular cancer patients. In the study, more than 90% of young, hearing-healthy participants developed ototoxicity after three cisplatin cycles, and patients treated with ACOU085 demonstrated clinically meaningful prevention of pure-tone audiometry threshold increases at affected frequencies compared to placebo. The company plans to present full results at the BIO International Convention in San Diego and submit findings for publication in a peer-reviewed journal.PR NewswirePromising First-in-Patient Results for ACOU085 (INN: Bimokalner) in Cisplatin-Induced OtotoxicityAcousia Therapeutics GmbH announced positive top-line efficacy results from its completed Phase 2a PROHEAR Study, evaluating ACOU085 (Bimokalner) as an otoprotective agent against cisplatin-induced hearing loss in testicular cancer patients. In participants who developed ototoxicity, treatment with a 6 mg transtympanic dose of ACOU085 resulted in clinically meaningful prevention of pure-tone audiometry threshold increases compared to placebo following cisplatin cycles. The company plans to present full results at a peer-reviewed journal and will seek collaboration partners at the BIO International Convention in San Diego to advance the next phase of clinical development.BioSpacePromising First-in-Patient Results for ACOU085 (INN: Bimokalner) in Cisplatin-Induced OtotoxicityAcousia Therapeutics announced positive top-line results from its Phase 2a PROHEAR study, showing ACOU085 prevented pure-tone audiometry threshold increases in cisplatin-induced ototoxicity. The study involved testicular cancer patients, with over 90% developing ototoxicity after three cisplatin cycles. Further analysis is ongoing for publication.PR NewswireAcousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced OtotoxicityAcousia Therapeutics GmbH announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study evaluating ACOU085 (INN: Bimokalner) for the prevention of cisplatin-induced ototoxicity. The multicenter trial enrolled young male patients with metastatic testicular cancer across fifteen leading university hospitals in Germany, using a split-body, placebo-controlled design to assess whether Bimokalner can prevent permanent hearing loss caused by cisplatin chemotherapy. The company's CEO reported that blinded preliminary results are promising, with full unblinded data expected in Q2–Q3 2026.PR NewswireAcousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR StudyAcousia Therapeutics GmbH announced it has enrolled 50% of patients in its ongoing Phase 2 PROHEAR Study evaluating ACOU085 (bimokalner) for preventing cisplatin-induced hearing loss in testicular cancer patients undergoing chemotherapy. The placebo-controlled, double-blind, split-body trial is being conducted at 13 German ENT university clinics, with enrollment on track to complete by the end of H2 2025. Cisplatin, used in over 500,000 cancer patients annually, causes clinically-relevant hearing loss in up to 80% of treated patients, representing a significant unmet medical need that ACOU085 aims to address.PR NewswireHearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-StudyAcousia Therapeutics GmbH announced the enrollment of the first patient in its Phase 2 PROHEAR-Study, a placebo-controlled clinical trial investigating the otoprotective drug ACOU085 in testicular cancer patients undergoing high-dose cisplatin chemotherapy. The split-body study design uses the patient as their own control, with the drug administered in one ear and placebo in the other prior to each chemotherapy cycle. Preclinical data demonstrated ACOU085's potential to reduce cisplatin-induced hearing loss and preserve outer hair cells from ototoxicity, a common irreversible side effect affecting cancer survivors' quality of life.FinSMEsAcousia Therapeutics Receives Investment from Esperante VenturesAcousia Therapeutics GmbH, a clinical-stage biotech company based in Tubingen, Germany, has received an investment from Esperante Ventures to enhance its drug development programs for hearing loss. The company plans to use these funds to advance its Kv7.4 activator programs and the ongoing clinical development of ACOU085, an otoprotective drug candidate currently in Phase 2 testing for preventing chemotherapy-induced hearing loss. This investment signifies the ongoing commitment to develop innovative treatments targeting hearing loss.PR NewswireHearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 TrialAcousia Therapeutics, a German clinical-stage biotech company, received approval from Germany\'s BfArM regulatory authority to conduct a Phase 2 clinical trial of its otoprotectant drug ACOU085 for preventing cisplatin-induced hearing loss in cancer patients. The Phase 2a multicenter, randomized, placebo-controlled trial will evaluate the drug\'s efficacy in young male patients diagnosed with testicular cancer, following successful Phase 1b results demonstrating excellent safety and tolerability. The company aims to address a significant unmet medical need, as cisplatin chemotherapy causes irreversible hearing loss in over 60% of cancer survivors, with first patient enrollment expected in late 2023.PR NewswireHearing loss company Acousia Therapeutics to present key learnings and data from lead development programs at US and European meetings in August and SeptemberAcousia Therapeutics GmbH, a clinical-stage biotech company based in Tübingen, Germany, will present data from its hearing loss drug candidates ACOU085 and ACOU082 at four industry conferences in Boston and London from August 29 to September 5, 2023. The company's ACOU085 candidate recently completed a successful first-in-man Phase 1b study and is expected to enter Phase 2a clinical testing for chemotherapy-induced hearing loss prevention by Q4 2023. ACOU082 is a systemically administered Kv7.4 activator in late preclinical development targeting age-related hearing loss.